One of these options is a combination of CDK4/6 inhibitors in combination with hormone therapy, which has been shown to be effective in women with advanced breast cancer negative for human epidermal growth factor receptor 2 (HER2), positive hormone receptor (HR+) (5). The gene discussed is ERBB2; the disease is breast carcinoma.